IceCure Medical (NASDAQ:ICCM) versus Precision Optics (NASDAQ:POCI) Head-To-Head Analysis

IceCure Medical (NASDAQ:ICCM) and Precision Optics (NASDAQ:POCI) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, profitability and analyst recommendations.

Volatility and Risk

IceCure Medical has a beta of 0.43, suggesting that its stock price is 57% less volatile than the S&P 500. Comparatively, Precision Optics has a beta of 0.34, suggesting that its stock price is 66% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for IceCure Medical and Precision Optics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IceCure Medical	2	0	3	0	2.20
Precision Optics	1	0	0	0	1.00

IceCure Medical currently has a consensus target price of $52.50, indicating a potential upside of 3,243.95%. Given IceCure Medical’s stronger consensus rating and higher probable upside, equities research analysts clearly believe IceCure Medical is more favorable than Precision Optics.

Profitability

This table compares IceCure Medical and Precision Optics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
IceCure Medical	-427.67%	-174.26%	-112.58%
Precision Optics	-11.51%	-23.92%	-13.05%

Insider & Institutional Ownership

0.6% of IceCure Medical shares are owned by institutional investors. Comparatively, 13.7% of Precision Optics shares are owned by institutional investors. 2.4% of IceCure Medical shares are owned by company insiders. Comparatively, 14.4% of Precision Optics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares IceCure Medical and Precision Optics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IceCure Medical	$3.38 million	1.59	-$15.06 million	($8.52)	-0.18
Precision Optics	$31.53 million	1.55	-$3.63 million	($0.46)	-9.70

Precision Optics has higher revenue and earnings than IceCure Medical. Precision Optics is trading at a lower price-to-earnings ratio than IceCure Medical, indicating that it is currently the more affordable of the two stocks.

Summary

Precision Optics beats IceCure Medical on 8 of the 14 factors compared between the two stocks.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.

About Precision Optics

Precision Optics Corporation, Inc. designs, develops, manufactures, and sells specialized optical and illumination systems and related components primarily in the United States and the European Economic Area. It offers medical instrumentation products, including endoscopes and endocouplers, as well as other custom imaging and illumination products, such as Microprecision lenses and micro medical cameras, and 3D endoscopes for use in minimally invasive surgical procedures by hospitals and physicians. The company also provides components and assemblies for industrial and military use. It markets its products to medical device companies. The company was incorporated in 1982 and is based in Gardner, Massachusetts.